Yong Chee-Chien, Yen Hsu-Ting, Cheng Yu-Fan, Dungca Leona Bettina, De Vera Raymond Joseph, Chen Itsuko Chih-Yi, Chen Chao-Long
Department of Surgery, Liver Transplantation Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung.
Department of Cardiovascular Surgery, Liver Transplantation Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung.
Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):662-668. doi: 10.21037/hbsn-23-616. Epub 2024 Jul 5.
The Meso-Rex bypass (MRB) is recognized as an effective treatment for portal hypertension secondary to extrahepatic portal vein occlusion (EHPVO) both in the pediatric and adult population, within or outside the context of liver transplantation. It is the preferred surgical treatment in most centers because not only does it addresses the portal hypertension, but also restores physiologic portal hepatopetal flow. However, the Rex recess, the landmark for this technique, may not be safely accessible in some patients. We present a 22-year-old male who underwent living donor liver transplant (LDLT) for neonatal hepatitis. He presented with variceal bleeding due to EHPVO at 13 years after transplant. Various endoscopic, radiologic, and surgical interventions were employed to address the recurrent gastrointestinal bleeding, but results have been unsatisfactory. We performed a meso-intrahepatic portal vein bypass (MIPVB), an innovative alternative to the MRB, for this patient with extensive post-operative adhesions, perihilar collaterals, and cavernous transformation. MIPVB creation in patients where the Rex recess is inaccessible is technically challenging. But with a multidisciplinary team approach, meticulous preoperative planning, and close follow-up, the authors have demonstrated that it is a safe and feasible option for patients with late-onset EHPVO after liver transplantation.
在肝移植背景下或非肝移植情况下,肠系膜上静脉-肝内门静脉左支分流术(MRB)被认为是治疗儿童和成人肝外门静脉阻塞(EHPVO)继发门静脉高压的有效方法。它是大多数中心首选的手术治疗方法,因为它不仅能解决门静脉高压问题,还能恢复生理性门静脉向肝血流。然而,该技术的标志性结构——雷克斯隐窝,在一些患者中可能无法安全显露。我们报告一名22岁男性,因新生儿肝炎接受了活体肝移植(LDLT)。他在移植后13年因EHPVO出现静脉曲张出血。为解决反复出现的胃肠道出血,采用了各种内镜、放射学和手术干预措施,但效果均不理想。对于这名有广泛术后粘连、肝门周围侧支循环和海绵样变性的患者,我们实施了肠系膜-肝内门静脉分流术(MIPVB),这是一种MRB的创新替代方法。在雷克斯隐窝无法显露的患者中创建MIPVB在技术上具有挑战性。但通过多学科团队协作、细致的术前规划和密切随访,作者证明了它对于肝移植后迟发性EHPVO患者是一种安全可行的选择。